Last reviewed · How we verify
REZIPAS (AMINOSALICYLIC ACID RESIN COMPLEX)
REZIPAS (generic name: AMINOSALICYLIC ACID RESIN COMPLEX) is a drug developed by BRISTOL MYERS SQUIBB. It is currently FDA-approved for Acute tuberculosis, Pulmonary tuberculosis.
REZIPAS, also known as 4-Aminosalicylic acid, is a small molecule dihydrofolate reductase inhibitor. It has been studied in clinical trials for various conditions, including Ulcerative Colitis, HIV Infections, and Sexually Transmitted Diseases, often in comparison to Budesonide MMX or Placebo.
At a glance
| Generic name | AMINOSALICYLIC ACID RESIN COMPLEX |
|---|---|
| Sponsor | BRISTOL MYERS SQUIBB |
| Target | Tyrosine-protein phosphatase non-receptor type 1, Cyclooxygenase, 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Acute tuberculosis
- Pulmonary tuberculosis
Common side effects
Key clinical trials
- The Efficacy and Tolerability of Bio-enhanced Curcumin (Diferuloylmethane) in the Induction of Remission in Patients With Mild to Moderate Ulcerative Colitis (Phase 3)
- Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum (N/A)
- Efficacy and Safety of Fecal Microbiota Transplantation for Ulcerative Colitis (Phase 2)
- The Effect of Household Bleach on Urine Color Among Pediatric Ulcerative Colitis Patients Treated With 5-aminosalicylic Acid (NA)
- The Individualized M(X) Drug-resistant TB Treatment Strategy Study A Strategy to Improve Treatment Outcomes in Patients With Drug-resistant TB (Phase 4)
- A Phase II Double-blind, Randomized, Comparator-controlled Study of the Safety and Efficacy of Zoenasa™ Rectal Gel (Mesalamine Plus N-acetylcysteine) in Subjects With Left-sided Ulcerative Colitis (Phase 2)
- Low Dose Metronomic Cyclophosphamide and Methotrexate Chemotherapy in Combination With Aspirin in Patients With Stage II-III Breast Cancer Who Fail to Achieve a Pathologic Complete Response After Neoa (NA)
- A Retrospective Study to Assess 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- REZIPAS CI brief — competitive landscape report
- REZIPAS updates RSS · CI watch RSS
- BRISTOL MYERS SQUIBB portfolio CI
Frequently asked questions about REZIPAS
What is REZIPAS?
What is REZIPAS used for?
Who makes REZIPAS?
What is the generic name of REZIPAS?
What development phase is REZIPAS in?
What does REZIPAS target?
Related
- Target: All drugs targeting Tyrosine-protein phosphatase non-receptor type 1, Cyclooxygenase, 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase
- Manufacturer: BRISTOL MYERS SQUIBB — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Acute tuberculosis
- Indication: Drugs for Pulmonary tuberculosis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing